# A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject

> **NCT05436678** · PHASE1 · COMPLETED · sponsor: **NeuroSense Therapeutics Ltd.** · enrollment: 19 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** PrimeC 748 mg
- **DRUG:** Ciprofloxacin 750 MG
- **DRUG:** Celecoxib 200mg

## Key facts

- **NCT ID:** NCT05436678
- **Lead sponsor:** NeuroSense Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-26
- **Primary completion:** 2022-08-19
- **Final completion:** 2022-10-20
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05436678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05436678, "A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05436678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*